Akyurek et al. analysed the gene rearrangement status of 239 DLBCL cases and found that patients with BCL6 rearrangements, particularly those with the non-GCB subtype, had a worse prognosis, suggesting that BCL6 rearrangement may be a biomarker of an aggressive disease course in non-GCB subgroups [17]. The gene discussed is BCL6; the disease is diffuse large B-cell lymphoma.